loader
Please Wait
Applying Filters...
menu
    • menu

    Digital Content for Opicapone

    Client Email Product
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    Bora Pharmaceuticals- Making success more certain.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.

    Virtual Booth

    Contact Supplier

    Axplora- The partner of choice for complex APIs.

    Virtual Booth

    Contact Supplier

    Fareva is a one-stop-shop for API/HPAPI, OSD & Sterile products, is USFDA, EMA and PMDA-inspected and has multiple NDA & ANDA filings.

    Virtual Booth

    Contact Supplier

    Menu

    Opicapone

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Amneal and BIAL Announce U.S. Licensing Agreement for ONGENTYS® (opicapone)
    Amneal and BIAL Announce U.S. Licensing Agreement for ONGENTYS® (opicapone)

    07 Dec 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20231207320607/en

    BUSINESSWIRE
    07 Dec 2023
    Share Share
    Neurocrine Presents Parkinson's Disease Patient Characteristics From ONGENTYS
    Neurocrine Presents Parkinson's Disease Patient Characteristics From ONGENTYS

    24 Oct 2022

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/neurocrine-biosciences-presents-real-world-parkinsons-disease-patient-characteristics-from-ongentys-opicapone-open-label-study-at-ana2022-301656404.html

    PRNEWSWIRE
    24 Oct 2022
    Share Share
    Neurocrine Presents Analysis of ONGENTYS Capsules Effect on COMT Activity
    Neurocrine Presents Analysis of ONGENTYS Capsules Effect on COMT Activity

    15 Sep 2022

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/neurocrine-biosciences-presents-new-post-hoc-analysis-of-ongentys-opicapone-capsules-effect-on-comt-activity-at-the-2022-mds-international-congress-301624809.html

    PRNEWSWIRE
    15 Sep 2022
    Share Share
    Bial Portela & Companhia Ontilyv (opicapone) Receives Approval in Europe
    Bial Portela & Companhia Ontilyv (opicapone) Receives Approval in Europe

    07 Mar 2022

    // EMA

    https://www.ema.europa.eu/en/documents/overview/ontilyv-epar-medicine-overview_en.pdf

    EMA
    07 Mar 2022
    Share Share
    Bial Portela's Biologic Optilyv (Opicapone) Receives Approval in Europe
    Bial Portela's Biologic Optilyv (Opicapone) Receives Approval in Europe

    07 Mar 2022

    // EMA

    https://www.ema.europa.eu/en/medicines/human/EPAR/ontilyv

    EMA
    07 Mar 2022
    Share Share
    New study investigating impact of ONGENTYS at the MDS Virtual Congress 2021
    New study investigating impact of ONGENTYS at the MDS Virtual Congress 2021

    14 Sep 2021

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2021-09-14/new-study-designs-investigating-impact-of-ongentys-opicapone-on-non-motor-symptoms-presented-for-first-time-at-the-mds-virtual-congress-2021

    PHARMIWEB
    14 Sep 2021
    Share Share